🇺🇸 FDA
Patent

US 11426397

Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6

granted A61KA61K31/198A61K31/445

Quick answer

US patent 11426397 (Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6) held by Takeda Pharmaceutical Company Limited expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/198, A61K31/445, A61K31/451, A61K31/4525